Project Grant R01CA301271
Award Date
2/21/25
Completion Date
1/31/30
Dollars Obligated
$391K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Tucson, AZ 85721, USA
Similar Awards
The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $400,000 Project Grant to Argosmd, Inc. to develop a low-cost, non-invasive microscopy tool called Mini-Reflectance Confocal Microscopy (Mini-RCM) to aid in skin cancer diagnosis and treatment. The key objectives are to: 1) Develop the Mini-RCM device with wide-field imaging capabilities and a size/weight similar to a dermatoscope, and 2) Evaluate the Mini-RCM performance by...
This Project Grant award, valued at $816,554.00, was provided by the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279). The award aims to develop and validate a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) that replicates tumor growth, surgical resection, and treatment with an oxaliplatin-based chemotherapy regimen. The research will assess the impact of surgery and tumor growth on the...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $1,239,420 to the University of Maryland, Baltimore (UMB) to conduct a longitudinal observational study on the role of interoception (the brain's processing of internal bodily sensations) in chemotherapy-induced peripheral neuropathy (CIPN) in 120 patients with breast or gastrointestinal cancer. The study, which will also include 60 age-matched...
This Project Grant award, funded by the National Science Foundation (NSF) under the Computer and Information Science and Engineering (CFDA 47.070) program, supports the development of an engineered cyber-physical system that combines advanced biological models with artificial intelligence methods to enable real-time, predictive precision medicine for cancer treatment. The $275,956 award to the University of Massachusetts Lowell aims to create a multi-organ-on-a-chip platform that can...
This federal Project Grant award of $568,151 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a real-time functional photoacoustic imaging platform to enable sensitive detection of prostate cancer tumors and accurate characterization of their aggressiveness. The key products and services to be delivered through this 5-year award include: Optimization of biocompatible polyacrylamide hydrogel nanoparticle (PAA NP) probes for...
This Project Grant award, with funding of $181,448.00 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), supports research to determine whether the drug dapansutrile, a selective NLRP3 inflammasome inhibitor, can alleviate and prevent chemotherapy-induced peripheral neuropathy (CIPN) in mouse models. The research will evaluate the effects of dapansutrile administration in mice treated with the chemotherapy drug paclitaxel, both in naïve and tumor-bearing animals. The...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $272,835 Project Grant under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program to the University of Arizona. The goal of this 4-year grant is to develop a new Probe-based Light Sheet Microscopy (PLSM) device and evaluate its clinical utility for in vivo imaging of the anal mucosa to aid in anal cancer screening. The research team, which...
The National Cancer Institute (NCI) awarded Carnegie Mellon University a $632,300 Project Grant under the Cancer Biology Research program (CFDA 93.396) to develop an integrated ultrahigh-throughput 3D volumetric super-resolution imaging system. This system will combine a multiscale fluorescence mesoscope with expansion microscopy to enable rapid, large-area 3D imaging at exceptional subcellular detail. The project aims to advance spatial biology in cancer research by visualizing interactions...
The National Cancer Institute (NCI) awarded a $658,336 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Rarecyte, Inc. to develop an "ORION2" instrument that will enable highly multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis. The key products and services to be delivered under this 3-year grant, which runs from June 1, 2025 to May 31, 2028, include: Developing an adaptive imaging system with automated control over...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to O2M Technologies LLC to develop a Multifunctional Imager (MFI) that can simultaneously acquire tissue oxygen pressure (pO2) and pH maps using electron paramagnetic resonance imaging (EPRI) techniques. The 12-month project aims to create a 25 MT Halbach-type permanent magnet, new multi-modal transmit-receive electronics, and the integrated MFI instrument. This...